MPA/DMBA-driven mammary carcinomas

Aitziber Buqué; Maria Perez-Lanzón; Giulia Petroni; Juliette Humeau; Norma Bloy; Takahiro Yamazaki; Ai Sato; Guido Kroemer; Lorenzo Galluzzi

doi:10.1016/bs.mcb.2020.08.003

MPA/DMBA-driven mammary carcinomas

Aitziber Buqué, Maria Perez-Lanzón, Giulia Petroni, Juliette Humeau, Norma Bloy, Takahiro Yamazaki, Ai Sato, Guido Kroemer, Lorenzo Galluzzi

Research output: Chapter in Book/Report/Conference proceeding › Chapter › peer-review

7 Scopus citations

Abstract

The polycyclic aromatic hydrocarbon 7,12-dimethylbenz[a]anthracene (DMBA, D) administered per os to wild-type female mice bearing slow-release medroxyprogesterone (MPA, M) pellets s.c. drives the formation of mammary carcinomas that recapitulate numerous immunobiological features of human luminal B breast cancer. In particular, M/D-driven mammary carcinomas established in immunocompetent C57BL/6 female mice (1) express hormone receptors, (2) emerge by evading natural immunosurveillance and hence display a scarce immune infiltrate largely polarized toward immunosuppression, (3) exhibit exquisite sensitivity to CDK4/CDK6 inhibitors, and (4) are largely resistant to immunotherapy with immune checkpoint blockers targeting PD-1. Thus, M/D-driven mammary carcinomas evolving in immunocompetent female mice stand out as a privileged preclinical platform for the study of luminal B breast cancer. Here, we provide a detailed protocol for the establishment of M/D-driven mammary carcinomas in wild-type C57BL/6 female mice. This protocol can be easily adapted to generate M/D-driven mammary carcinomas in female mice with most genetic backgrounds (including genetically-engineered mice).

Original language	English
Title of host publication	Carcinogen-driven mouse models of oncogenesis
Editors	Lorenzo Galluzzi, Lorenzo Galluzzi, Lorenzo Galluzzi, Aitziber Buqué
Publisher	Academic Press Inc.
Pages	1-19
Number of pages	19
Volume	163
ISBN (Print)	9780128225349
DOIs	https://doi.org/10.1016/bs.mcb.2020.08.003
State	Published - Jan 2021
Externally published	Yes

Publication series

Name	Methods in Cell Biology
Volume	163
ISSN (Print)	0091-679X

Keywords

Chemotherapy
Immunotherapy
KRAS
PI3K
Radiation therapy
Targeted anticancer agents
Carcinoma
Humans
Mice, Inbred C57BL
Animals
Mammary Neoplasms, Experimental/chemically induced
9,10-Dimethyl-1,2-benzanthracene
Female
Mice
Medroxyprogesterone Acetate
Breast Neoplasms/drug therapy

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1016/bs.mcb.2020.08.003

Cite this

Buqué, A., Perez-Lanzón, M., Petroni, G., Humeau, J., Bloy, N., Yamazaki, T., Sato, A., Kroemer, G., & Galluzzi, L. (2021). MPA/DMBA-driven mammary carcinomas. In L. Galluzzi, L. Galluzzi, L. Galluzzi, & A. Buqué (Eds.), Carcinogen-driven mouse models of oncogenesis (Vol. 163, pp. 1-19). (Methods in Cell Biology; Vol. 163). Academic Press Inc.. https://doi.org/10.1016/bs.mcb.2020.08.003

@inbook{492356fb2b8247a391e91f31626a4ef0,

title = "MPA/DMBA-driven mammary carcinomas",

abstract = "The polycyclic aromatic hydrocarbon 7,12-dimethylbenz[a]anthracene (DMBA, D) administered per os to wild-type female mice bearing slow-release medroxyprogesterone (MPA, M) pellets s.c. drives the formation of mammary carcinomas that recapitulate numerous immunobiological features of human luminal B breast cancer. In particular, M/D-driven mammary carcinomas established in immunocompetent C57BL/6 female mice (1) express hormone receptors, (2) emerge by evading natural immunosurveillance and hence display a scarce immune infiltrate largely polarized toward immunosuppression, (3) exhibit exquisite sensitivity to CDK4/CDK6 inhibitors, and (4) are largely resistant to immunotherapy with immune checkpoint blockers targeting PD-1. Thus, M/D-driven mammary carcinomas evolving in immunocompetent female mice stand out as a privileged preclinical platform for the study of luminal B breast cancer. Here, we provide a detailed protocol for the establishment of M/D-driven mammary carcinomas in wild-type C57BL/6 female mice. This protocol can be easily adapted to generate M/D-driven mammary carcinomas in female mice with most genetic backgrounds (including genetically-engineered mice).",

keywords = "Chemotherapy, Immunotherapy, KRAS, PI3K, Radiation therapy, Targeted anticancer agents, Carcinoma, Humans, Mice, Inbred C57BL, Animals, Mammary Neoplasms, Experimental/chemically induced, 9,10-Dimethyl-1,2-benzanthracene, Female, Mice, Medroxyprogesterone Acetate, Breast Neoplasms/drug therapy",

author = "Aitziber Buqu{\'e} and Maria Perez-Lanz{\'o}n and Giulia Petroni and Juliette Humeau and Norma Bloy and Takahiro Yamazaki and Ai Sato and Guido Kroemer and Lorenzo Galluzzi",

year = "2021",

month = jan,

doi = "10.1016/bs.mcb.2020.08.003",

language = "English",

isbn = "9780128225349",

volume = "163",

series = "Methods in Cell Biology",

publisher = "Academic Press Inc.",

pages = "1--19",

editor = "Lorenzo Galluzzi and Lorenzo Galluzzi and Lorenzo Galluzzi and Aitziber Buqu{\'e}",

booktitle = "Carcinogen-driven mouse models of oncogenesis",

address = "United States",

}

Buqué, A, Perez-Lanzón, M, Petroni, G, Humeau, J, Bloy, N, Yamazaki, T, Sato, A, Kroemer, G & Galluzzi, L 2021, MPA/DMBA-driven mammary carcinomas. in L Galluzzi, L Galluzzi, L Galluzzi & A Buqué (eds), Carcinogen-driven mouse models of oncogenesis. vol. 163, Methods in Cell Biology, vol. 163, Academic Press Inc., pp. 1-19. https://doi.org/10.1016/bs.mcb.2020.08.003

MPA/DMBA-driven mammary carcinomas. / Buqué, Aitziber; Perez-Lanzón, Maria; Petroni, Giulia et al.
Carcinogen-driven mouse models of oncogenesis. ed. / Lorenzo Galluzzi; Lorenzo Galluzzi; Lorenzo Galluzzi; Aitziber Buqué. Vol. 163 Academic Press Inc., 2021. p. 1-19 (Methods in Cell Biology; Vol. 163).

Research output: Chapter in Book/Report/Conference proceeding › Chapter › peer-review

TY - CHAP

T1 - MPA/DMBA-driven mammary carcinomas

AU - Buqué, Aitziber

AU - Perez-Lanzón, Maria

AU - Petroni, Giulia

AU - Humeau, Juliette

AU - Bloy, Norma

AU - Yamazaki, Takahiro

AU - Sato, Ai

AU - Kroemer, Guido

AU - Galluzzi, Lorenzo

PY - 2021/1

Y1 - 2021/1

N2 - The polycyclic aromatic hydrocarbon 7,12-dimethylbenz[a]anthracene (DMBA, D) administered per os to wild-type female mice bearing slow-release medroxyprogesterone (MPA, M) pellets s.c. drives the formation of mammary carcinomas that recapitulate numerous immunobiological features of human luminal B breast cancer. In particular, M/D-driven mammary carcinomas established in immunocompetent C57BL/6 female mice (1) express hormone receptors, (2) emerge by evading natural immunosurveillance and hence display a scarce immune infiltrate largely polarized toward immunosuppression, (3) exhibit exquisite sensitivity to CDK4/CDK6 inhibitors, and (4) are largely resistant to immunotherapy with immune checkpoint blockers targeting PD-1. Thus, M/D-driven mammary carcinomas evolving in immunocompetent female mice stand out as a privileged preclinical platform for the study of luminal B breast cancer. Here, we provide a detailed protocol for the establishment of M/D-driven mammary carcinomas in wild-type C57BL/6 female mice. This protocol can be easily adapted to generate M/D-driven mammary carcinomas in female mice with most genetic backgrounds (including genetically-engineered mice).

AB - The polycyclic aromatic hydrocarbon 7,12-dimethylbenz[a]anthracene (DMBA, D) administered per os to wild-type female mice bearing slow-release medroxyprogesterone (MPA, M) pellets s.c. drives the formation of mammary carcinomas that recapitulate numerous immunobiological features of human luminal B breast cancer. In particular, M/D-driven mammary carcinomas established in immunocompetent C57BL/6 female mice (1) express hormone receptors, (2) emerge by evading natural immunosurveillance and hence display a scarce immune infiltrate largely polarized toward immunosuppression, (3) exhibit exquisite sensitivity to CDK4/CDK6 inhibitors, and (4) are largely resistant to immunotherapy with immune checkpoint blockers targeting PD-1. Thus, M/D-driven mammary carcinomas evolving in immunocompetent female mice stand out as a privileged preclinical platform for the study of luminal B breast cancer. Here, we provide a detailed protocol for the establishment of M/D-driven mammary carcinomas in wild-type C57BL/6 female mice. This protocol can be easily adapted to generate M/D-driven mammary carcinomas in female mice with most genetic backgrounds (including genetically-engineered mice).

KW - Chemotherapy

KW - Immunotherapy

KW - KRAS

KW - PI3K

KW - Radiation therapy

KW - Targeted anticancer agents

KW - Carcinoma

KW - Humans

KW - Mice, Inbred C57BL

KW - Animals

KW - Mammary Neoplasms, Experimental/chemically induced

KW - 9,10-Dimethyl-1,2-benzanthracene

KW - Female

KW - Mice

KW - Medroxyprogesterone Acetate

KW - Breast Neoplasms/drug therapy

UR - http://www.scopus.com/inward/record.url?scp=85092014842&partnerID=8YFLogxK

U2 - 10.1016/bs.mcb.2020.08.003

DO - 10.1016/bs.mcb.2020.08.003

M3 - Chapter

C2 - 33785159

AN - SCOPUS:85092014842

SN - 9780128225349

VL - 163

T3 - Methods in Cell Biology

SP - 1

EP - 19

BT - Carcinogen-driven mouse models of oncogenesis

A2 - Galluzzi, Lorenzo

A2 - Buqué, Aitziber

PB - Academic Press Inc.

ER -

MPA/DMBA-driven mammary carcinomas

Abstract

Publication series

Keywords

UN SDGs

Access to Document

Other files and links

Fingerprint

Cite this